Press release
Liver Cancer Pipeline Report Reveals Promising Drug Candidates and Treatment Strategies | Companies- GSK, Eureka Therapeutics, Takeda, Polaris Group, and Others
Liver Cancer Pipeline
To explore more information on the latest breakthroughs in the Liver Cancer Pipeline treatment landscape of the report, click here @ Liver Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Liver Cancer Overview
Liver cancer is a cancer that originates in the liver, and is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. Primary liver cancer, or hepatocellular carcinoma (HCC), is the fifth most common cancer in males and the seventh most common cancer in females, and is the third leading cause of cancer-related death worldwide.
Key Takeaways from the Liver Cancer Pipeline Report
• DelveInsight's Liver Cancer Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Liver Cancer.
• The leading Liver Cancer Companies include Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, , Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others are evaluating novel liver cancer drugs candidate to improve the treatment landscape.
• Promising Liver Cancer Pipeline therapies include Tiragolumab, VG161, IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561, ET140203, Q702, Relatlimab, LioCyx-M, DKN-01, SD-101, BO-112, RO7119929, PV-10, PF-07263689, E7386, GEN2, TTI-101, MRG002, TAK-500, TAEK-VAC-HerBy, INT230-6, ARB202, QBS10072S, A166, NBTXR3, TBI-1301, CVM-1118, Namodenoson, STP705, BLU-554, SRF388, YIV-906, Tivozanib, KN046, DNAJB1-PRKACA, PTX-9908, SHR-8068, T-ACE Oil, SynOV1.1, SCT-I10A, ABX196, GT90001, ABSK-011, ADI-PEG20, HLX07, VG161, Vax NK/HCC, ERY974, Ociperlimab, HX008, CS1003, ATG-008, Icaritin, P1101, CT0181, LCAR-H93T Cells, and others.
• In May 2022, SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC. Confirmed partial responses (PR) were observed in two patients who received SRF388 monotherapy treatment: one in non-small-cell lung cancer (NSCLC) (previously reported) and one in clear cell renal cell carcinoma (RCC). In addition, a PR was observed in a patient who was treated with SRF388 in combination with pembrolizumab for hepatocellular carcinoma (HCC).
• In October, 2022, the U.S. Food and Drug Administration (FDA) approved a combination of the immunotherapy drugs durvalumab (Imfinzi®) plus the experimental drug tremelimumab for people with unresectable hepatocellular cancer, the most common type of liver cancer. The FDA approval was based on results of the clinical trial HIMALAYA involving 1,117 patients, led by gastrointestinal medical oncologist Ghassan Abou-Alfa at Memorial Sloan Kettering Cancer Center (MSK).
• In October 25, 2022, the US Food and Drug Administration (FDA) has granted approval for AstraZeneca's Imjudo (tremelimumab) plus Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), a kind of liver cancer.
For further information, refer to the detailed Liver Cancer Unmet Needs, Liver Cancer Market Drivers, and Liver Cancer Market Barriers, click here for Liver Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Liver Cancer Emerging Drugs Profile
• SRF388: Surface Oncology
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface Oncology has identified particular tumor types, including liver, kidney and lung cancer, where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors. SRF388 targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with other cancer therapies including anti-PD-1 therapy, as well as potent anti-tumor effects as a monotherapy.
• MTL-CEBPA: MiNA Therapeutics
MTL-CEBPA is a new medicine initially being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-α protein to normal levels using the RNA Activation mechanism.
• APX3330: Ocuphire Pharma
ALK-1 antibody is a potential first-in-class, fully human IgG2 neutralizing monoclonal antibody that inhibits BMP9, TGFβ through ALK-1 receptor-mediated signal transduction and tumor angiogenesis.
• Fostroxacitabine bralpamide: Medivir
Fostroxacitabine bralpamide (also named MIV-818) is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer.
• CDX-527: Celldex Therapeutics
CDX-527 is a bispecific antibody composed of Celldex's proprietary PD-L1 and CD27 human antibodies. CDX-527 combines blockade of the PD-1 pathway with T cell costimulation through CD27 into one molecule using an IgG1-ScFv format. Preclinical data demonstrate CDX-527 is more potent than the combination of anti-PD-L1 and anti-CD27 antibodies in T cell activation and anti-tumor activity. CDX-527 has direct antibody-dependent cellular cytotoxicity (ADCC) against CD27 or PD-L1 expressing tumor cells. In addition, CDX-527 exhibits an antibody-like pharmacokinetic profile without concerning toxicity in preclinical models.
Request a sample and discover the recent advances in Liver Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Liver Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Liver Cancer Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies Liver Cancer. The companies which have their Liver Cancer drug candidates in the most advanced stage, i.e. phase III include, Polaris Group.
Dive deep into rich insights for drugs for Liver Cancer Pipeline, click here @ Liver Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Liver Cancer Pipeline Report
• Coverage- Global
• Liver Cancer Companies- Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, , Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others are evaluating novel liver cancer drugs candidate to improve the treatment landscape.
• Liver Cancer Pipeline therapies- Tiragolumab, VG161, IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561, ET140203, Q702, Relatlimab, LioCyx-M, DKN-01, SD-101, BO-112, RO7119929, PV-10, PF-07263689, E7386, GEN2, TTI-101, MRG002, TAK-500, TAEK-VAC-HerBy, INT230-6, ARB202, QBS10072S, A166, NBTXR3, TBI-1301, CVM-1118, Namodenoson, STP705, BLU-554, SRF388, YIV-906, Tivozanib, KN046, DNAJB1-PRKACA, PTX-9908, SHR-8068, T-ACE Oil, SynOV1.1, SCT-I10A, ABX196, GT90001, ABSK-011, ADI-PEG20, HLX07, VG161, Vax NK/HCC, ERY974, Ociperlimab, HX008, CS1003, ATG-008, Icaritin, P1101, CT0181, LCAR-H93T Cells, and others.
• Liver Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Liver Cancer Mergers and acquisitions, Liver Cancer Licensing Activities @ Liver Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Liver Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ADI-PEG20: Polaris Group
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Brivanib alaninate: ZAI Lab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ABSK 011: Abbisko Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Liver Cancer Key Companies
21. Liver Cancer Key Products
22. Liver Cancer- Unmet Needs
23. Liver Cancer- Market Drivers and Barriers
24. Liver Cancer- Future Perspectives and Conclusion
25. Liver Cancer Analyst Views
26. Liver Cancer Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liver Cancer Pipeline Report Reveals Promising Drug Candidates and Treatment Strategies | Companies- GSK, Eureka Therapeutics, Takeda, Polaris Group, and Others here
News-ID: 3076235 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Liver
Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Liver Metastases Treatment Market Size By 2025?
The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…
